Seasons greetings from the ProTarget Study
🌟 Reflecting on 2024: Milestones in ProTarget 🌟 As the year concludes, we are happy to share highlights from ProTarget in 2024, which include the following major milestones: 🧬 Inclusion of 300 patients for biomarker-matched targeted treatment outside current EMA-label 🌍 Expansion of evidence for targeted treatments in collaboration with other DRUP-like Clinical Trials 🏆 Recognition of our innovative trial design at Danish Cancer Research Days ❤️ Sharing of patient stories that inspire us to continue our journey We are deeply grateful to our patients and their families for their participation, as well as our partners and supporters. With your trust and support, we are able to succeed on our mission. As we look forward to 2025, we will continue to push the boundaries of #precisiononcology by expanding our clinical and translational research activities striving to make precision medicine a reality for all cancer patients. Thank you for being part of this journey! 👇 Read the full story here Ulrik Niels Lassen Kristoffer Rohrberg Rikke Eefsen lise søndergaard Julie Gehl Annette Raskov Kodahl Lars Henrik Jensen Britt Elmedal Laursen Morten Ladekarl Tina Kringelbach Kristina Vile Jensen Tina Krogh Hansen Martin Højgaard Iben Spanggaard Rigshospitalet, Afdeling for Kræftbehandling, Herlev og Gentofte Hospital, Onkologisk Afdeling og Palliativ Enhed, SUH, Onkologisk Afdeling, OUH, SKA - Sammenslutningen af Kræftafdelinger, Dansk Selskab for Klinisk Onkologi (DSKO), #SammenOmKræft #Rigshospitalet #ProTargetDenmark #DKD2024 #ESMO24 #DRUP #IMPRESSnorway FINPROVE trial PRIME-ROSE PCM4EU - Personalised Cancer Medicine for all EU citizens https://lnkd.in/dwrUJCa6
